Login / Signup

Oxidized phospholipids and lipoprotein(a): An update.

Amalia Despoina KoutsogianniEvangelos LiberopoulosKonstantinos TellisAlexandros D Tselepis
Published in: European journal of clinical investigation (2021)
Over the past few years, there has been an undiminished interest in lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs), mainly carried on this lipoprotein. Elevated Lp(a) has been established as an independent causal risk factor for cardiovascular disease. OxPLs play an important role in atherosclerosis. The main questions that remain to be answered, however, is to what extent OxPLs contribute to the atherogenicity of Lp(a), what effect hypolipidaemic medications may have on their levels and the potential clinical benefit of their reduction. This narrative review aimed to summarize currently available data on OxPLs and cardiovascular risk, as well as the effect of established and emerging hypolipidaemic medications on Lp(a)-OxPLs.
Keyphrases
  • low density lipoprotein
  • cardiovascular disease
  • fatty acid
  • type diabetes
  • machine learning
  • big data
  • metabolic syndrome
  • artificial intelligence
  • deep learning